Site Search:

Home

Outsourcing Reports

Outsourcing Showcase

Reports Store

Outsourcing Directory

Events

Advertising

News

15 Items, CDN $ 12345

Go Back

Booming Global Obesity Drug Market RNCOS December 2008 Report Code: RNCOSOB CDN $ 799 Buy Abstract 80 Pages "“Booming Global Obesity Drug Market”, our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it’s expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets. The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi’s Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch. The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters. Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China’s obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market. Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market. Our report provides forecast on § Global obesity market § Xenical revenue § Meridia revenue § Alli revenue § Global prevalence of obesity § Prevalence of obesity in major developed and emerging markets Profiling on Key Players This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company." Table of Contents "1. Analyst View 2. The Global Obesity Epidemic 2.1 Defining Obesity 2.2 Prevalence of Obesity 2.3 The Cost of Obesity 2.4 Obesity is Linked to Higher Rates of Chronic Conditions 2.5 Obese Spend Significantly Higher on Healthcare 3. Available Weight-loss Techniques & Products 3.1 Weight-loss Surgery 3.2 Liposuction 3.3 Weight-loss Foods & Drinks 3.4 Diet Centres 3.5 Weight-loss Drugs 4. Obesity Drugs Market 4.1 Market Opportunity Assessment 4.2 Key Weight-loss Drugs 4.2.1 Alli 4.2.1.1 Market Performance 4.2.1.2 Critical Success & Risk Factors 4.2.2 Xenical 4.2.2.1 Market Performance 4.2.2.2 Critical Success & Risk Factors 4.2.3 Acomplia 4.2.3.1 Market Performance 4.2.3.2 Critical Success & Risk Factors 4.2.4 Meridia 4.2.4.1 Market Performance 4.2.4.2 Critical Success & Risk Factors 4.3 Weight-loss Drugs under Clinical Trials 5. Obesity in Developed Markets - A Brief Profile 5.1 US 5.2 Japan 5.3 Germany 5.4 UK 5.5 France 5.6 Italy 5.7 Spain 6. Obesity in Emerging Markets - A Brief Profile 6.1 Russia 6.2 India 6.3 Brazil 6.4 China 7. Critical Success Factors 7.1 Expanding Waistlines 7.2 High Unmet Needs 7.3 Self-Consciousness & Fulfillment 7.4 Strong Pipeline 8. Critical Risk Factors 8.1 High Failure Rate 8.2 High Consumer Demand 8.3 Reimbursement Issues 8.4 Side Effects 9. Key Company Profiles 9.1 Abbott Laboratories 9.2 Roche Holding Ltd 9.3 Sanofi-Aventis 9.4 GlaxoSmithKline plc 9.5 Pfizer Inc."

Using the Site   Privacy & Security Statement
Advertise with us   Directory Guide
CanBiotech Newsletters

© 2000-2010 CanBiotech™ Inc.